ncmlsg.org

Advancing CML Care

Nordic CML Study group

News

Stay updated with NCMLSG. This page section shares brief updates on projects, publications, guideline changes, meeting highlights, and practical announcements. Each post links to more detail so you can catch up fast and dive deeper when you need to.

Register

Register for renewed membership You need to register again for the new web site and since our old members list is outdated. With an account you can save your details for quicker registrations, and access

Read More »

New website

Welcome to our new website Welcome to NCMLSG. We’re a Nordic collaboration working to advance care, education, and research in chronic myeloid leukemia and related myeloproliferative neoplasms. This site is here to make it easier

Read More »

Events

Our events bring together clinicians, nurses, scientists, and partners to share the latest in CML care and research. Explore the calendar, learn more about each session, and secure your spot with quick registration.

Our aim

We aim is to cure CML patients without allogeneic transplantation and improve treatment of CML .

Our group consists of scientists, clinicians and nurses interested in CML. We work all over the Nordic region, mainly at University Hospitals but also hematologists working in other hospitals are active in our group. We meet twice a year (generally April and November).

Our activities have been supported by partners in pharmaceutical industry, and we regard this cooperation as an essential element for progress

We will pursue our aim by conducting clinical trials and attached to such trials address scientific questions in the laboratory. Sampling of patient material during trials is key to solve scientific problems that may direct us toward new treatments.

Our clinical trials have been focused on use of different tyrosine kinase inhibitors, also combined with pegylated interferon. For patients who do well we have participated in discontinuation projects (we contributed 25% of patients to the big EuroSKI project, an European LeukemiaNet study. See http://www.leukemia-net.org

Guideline-based treatment depends on excellent assessment of disease burden. Standardization efforts for PCR measurement of residual disease have been carried out and continue in anEuropean framework (EUTOS).

Spread of knowledge through education activities, with CML school for young hematologists and an open CML Education Symposium have been arranged every second year. Treatment guidelines have been issued in all countries and on the European level.

Henrik Hjorth-Hansen,

NCMLSG – chairman

Steering Group

The Nordic CML Study Group (NCMLSG) is guided by a dedicated team of experts in hematology, research, and clinical practice. Our steering group consists of leading specialists from across the Nordic region, committed to advancing the treatment of Chronic Myeloid Leukemia (CML).

Henrik HjH
Henrik Hjorth-Hansen

Chairman, Trondheim

Perttu
Perttu Koskenvesa

Helsinki

Lene_Udby
Lene Udby

Roskilde

Siim Kalter
Siim Kalter
Andreja Dimitrijevic
Andreja Dimitrijevic
Stina Söderlund
Stina Söderlund
Anna Lübking
Anna Lübking
Waleed Majeed

Contact us

We are committed to advancing medical knowledge and collaboration. Whether you have questions, wish to contribute, or need further information about our study group, we’d love to hear from you. Connect with us to join a network of dedicated professionals striving for excellence in healthcare.